Disease Landscape and Forecast 인사이트
종합적인 시장 정보와 실행 가능한 인사이트를 통해 장기적인 질병 전략을 최적화하세요.
COPD in the EU5: (How Will Prescribers and Payers Integrate Additional LABA- and LAMA-Containing Products Within Increasingly Constrained Budgets?) | Physician & Payer Forum | EU5 | 2014
Long-acting beta2 agonist (LABA)/long-acting muscarinic antagonist (LAMA) fixed-dose combinations (FDCs) have the potential to be first-line chronic obstructive pulmonary disorder (COPD) therapies…
Nephrology (Renal Anemia and Bone and Mineral Metabolism) | TreatmentTrends | US | Q2 2014
This quarterly report provides a detailed analysis of emerging and current therapies in nephrology based on responses from surveyed U.S. nephrologists. Emphasis is on anemia management (ESAs and IV…
SPECIAL REPORT: The Launches of Opsumit, Adempas, and Orenitram into the Pulmonary Arterial Hypertension Market
Pulmonary arterial hypertension (PAH) is a severe and debilitating disease, with rapid disease progression and high rates of mortality. As a consequence, the necessity for effective treatments are…
Chronic Myeloid Leukemia (Prescribing Decisions and Payer Landscape in a Crowded and Changing U.S. Market) | Physician & Payer Forum | US | 2014
Despite the comparatively low incidence of chronic myeloid leukemia (CML) in the United States, patient management requires extended durations of therapy, which in turn translates into a…
Global Consequences of Smoking Cessation: NSCLC Incidence over the Next Two Decades
The strongest risk factor that drives change in the incidence of non-small-cell lung cancer (NSCLC) is the historical prevalence of smoking. The long lag between the initiation of tobacco use and…
Non-Small-Cell Lung Cancer (Previously Treated EGFR Wild-Type/Untested) | Decision Base | US/EU | 2014
Of the Several Exciting Agents in Late-Stage Development, Do Any Have the Potential to Dramatically Improve Survival? Non-small-cell lung cancer (NSCLC) accounts for approximately 85% of all…
Non-Small-Cell Lung Cancer (Previously Treated EGFR Wild-Type/Untested) | DecisionBase | US/EU5/Asia Pacific | 2014
Of the Several Exciting Agents in Late-Stage Development, Do Any Have the Potential to Dramatically Improve Survival? Non-small-cell lung cancer (NSCLC) accounts for approximately 85% of all…
U.S. Prescriber and Payer Receptivity to Emerging Agents for Treatment-Resistant Depression Amid a Crowded and Increasingly Genericized Market | Physician & Payer Forum | US | 2014
Major depressive disorder (MDD) continues to be a highly prevalent psychiatric disorder. Over 5 million drug-treated MDD patients in the United States fail to respond adequately to treatment with…
Hepatitis C Virus (Primary Care Physicians in an Interferon-Free World: How Will the Availability of Safer and More Effective Oral Therapies Impact the Role of PCPs in Treating HCV Patients?) | Physician & Payer Forum | US | 2014
The market opportunity for hepatitis C virus (HCV) is marked by a large prevalent population and high unmet medical need due to the suboptimal tolerability and efficacy of early, interferon-based…
